Galderma Group AG: Broad-Based Revenue Outperformance and Lower Execution Risk Support Buy Rating

In a report released today, Benjamin Jackson CFA from Jefferies reiterated a Buy rating on Galderma Group AG, with a price target of CHF190.00.

Benjamin Jackson CFA has given his Buy rating due to a combination of factors that underscore Galderma Group AG’s strong operating momentum and reduced execution risk. The company’s first-quarter revenue exceeded consensus by roughly 4%, with each major business line delivering sales above market expectations, which supports confidence in both current performance and forward earnings potential.

The outperformance was broad-based, including notable strength in Therapeutic Dermatology and continued growth in Injectable Aesthetics, even after accounting for some favorable U.S. phasing effects. Management also reaffirmed its 2026 outlook while indicating that the targets are now less risky and already incorporate U.S. drug tariff headwinds, leading Jackson to view the risk‑reward profile as attractive and supportive of a Buy recommendation.

Jackson CFA covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Zealand Pharma, and Genmab. According to TipRanks, Jackson CFA has an average return of 6.5% and a 52.38% success rate on recommended stocks.

In another report released on April 20, Barclays also maintained a Buy rating on the stock with a CHF200.00 price target.